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It is well-known that agents influencing upon thrombocyte aggregation effect also on both 
morbidity and mortality rate from cerebro-vascular disease ( C V D ) . In this aspect, Aspirin therapy 
was examined in detail more than one decade ago. A n opinion was adopted tnat low Aspirin doses 
were not less effective than higher ones [2]. Certain investigations were directed towards 
experiments with combined action on patients with initial cerebro-vascular insufficiency and 
stroke. In this aspect, the idea of C V D prophylaxis by means of the combination of an 
antiaggregant and an antioxidant is of interest, indeed Although specific function of tocopherol 
(vit. E ) is not completely clarified yet its participation as an antioxidant in unsaturated fatty acid 
metabolism is already proved [1,3,4]. 
The purpose of the present study was the comparison of the results from late C V D prophylaxis 
by an antiaggregant alone and by the combined treatment with an antiaggregant-antioxidant. 
MATERIAL AND METHODS 
?reverse 
development or with insignificant neurological deficit dating at least bade up to 3 months, 108 
ones with transitory ischemic attacks ( T I A ) , and 76 ones with latent cerebro-vascular 
nraifryirau^) were covered m 
of 50 mg and Aspirin in a dose of 125 mg daily, The aeddenteof the first two groups were defined 
as acute focal disorders of cerebral function caused by insufficiency in both carotid and 
vertebrobasilar pods and differing in duration of manifestations. A special questionnaire 
(Hadzhiev and Molhov) was applied in patients of the third group in order to detect the latent 
cerebro-vascular disease. Patients' complaints were at least two out of a total group of 5 symptoms 
ear-noise, mental deficiency reduction and poor memory which occurred 
at least once a week provoked by neuropsychical or physical stress. A group of276 patients divided 
into 3 subgroups were used as controls (79patients with latent cerebro-vascular insufficiency, 106 
cases with T I A and 91 ones with stroke). They were treated with Aspirin in a dose of 125 mg daily 
only. A dietary and therapeutic regimen was observed in both groups (series) in correspondence 
to the basic diseases (arterial hypertension, heart disease, etc.). Patients were interviewed two 
times yearly. Two main criteria were registered as final results: appearance of a stroke and stroke 
death. The following excluding criteria were considered: miscont rolled hypertension, uremia, 
diabetes, peptic ulcer, haemorrhagic diathesis, precursory antiaggregant and antioxidant therapy. 
The investigation started in mid-1987 and was planned for a 5-year period. These present results 
are based on a 24-month long observation. They are statistically processed by the method of 
variation analysis. 
RESULTS AND DISCUSSION 
A total of 405 patients from both series were folio we d - up until the end of the two-year period 
and correspond* ngly treated (198 patients with Aspirin and vit. Е but 207ones with Aspirin alone) 
(table J ) 
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Table 1 
Patients with C V D and "Aspirin + vit. E " treatment 
Patients with C V D Aspirin + V i t . E Aspirin alone 
Latent C V I 








T o t a l 276 276 
The dropping out was caused by therapeutic side-effects, intercurrent diseases and non-medical 
factors (table 2). 
T a b l e 2 
Outcome in all patients 
Kind of patients Treatment with: 





Followed-up for 24 months 
' Drop outs 
















It should be noted that there was no statistically significant difference between both groups 
concerning the presence of side-effects of the treatment. A stroke and death of cardiovascular 
disease was registered in 103 patients (in 50 ones in the series "Aspirin and vit. E " and in 53 ones 
in the series "Aspirin alone") (table 3). 
A total of 25 patients of the control group and 32 ones of the second group died. This difference 
is statistically insignificant (p > 0,05). No significant difference could be established between the 
number of patients in the first and second subgroups of the control group. The analysis of the 
results of our study related to nosological units insisted us to conclude that patients with stroke 
dominated in the patients' group with latent C V D on Aspirin therapy only - in 31 per cent against 
in 12,5 per cent when patients treated with both Aspirin and vit. Е were concerned (p>0,05) 
(table 4). 
112 P. Mangov 






Non-cerebral deaths due to 
myocardial infarction 
sudden deaths 




T o t a l 















21 > 0,05 
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53 > 0,05 
T a b l e 4 
Stroke patients with C V D and "Aspirin - vit. E " treatment 
Patients with C V D Aspirin + vit. Е Aspirin alone P < 
n n 
Latent С V I 











T o t a l 32 29 0,05 
However, the small number of cases does not allow us to draw any more general conclusions. 
The investigation presented above will continue for the whole 5-ycar period. Our results reflect 
our personal observations. They are based on a relatively short time and small number of patients. 
That is why at this stage of the trial any explicit conclusions would be jumped to. If the outlined 
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tendency to a lower incidence rate of stroke complications in the patients with late C V D under 
combined treatment with Aspirin and Vit. Е is confirmed in future, too, it seems acceptable that 
this therapeutic combination of "antiaggregant and antioxidant" is encouraging, indeed. 
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ПОЗДНЯЯ ПРОФИЛАКТИКА МОЗГОВО-СОСУДИСТОЙ 
БОЛЕЗНИ 
П. Мангов 
Р Е З Ю М Е 
Высокая инвалидность и смертность в результате мозгово-сосудиетой болезни требует применения ряда 
профилактических мероприятий. В то время как мировой опыт, связанный с применением аятиагрегантов 
значителен, комбинация "антиокендант-антнагрегант" нуждается в дополнительных исследованиях. 
Было проведено проспективное наблюдение 76 больных с латентной и 108 больных с относительной 
недостаточностью мозгового кровообращения, а также 92 больных, перенесших мозговой инсульт с 
незначительным неврологическим дефицитом. Больные принимали 125 мг аспирина и 50 мг витамина Е в день. 
Пациенты другой гомогенной группы принимали только аспирин. Два раза в год проводился разговор с 
пациентами по поводу результата проведенного лечения. Учитывались появление новых ТИА, нового инсульта, 
смерть от сердечно-сосудистых заболеваний. Результаты профилактического лечения больных посредством 
комбинации "аспирин - витамин Е" можно считать обнадеживающими. 
8 Scripta Scientifica Mcdica 
